Antenatal Low Dose Magnesium Sulphate for Foetal Neuroprotection in Preterm Birth Versus Control: A Comparative Prospective Cohort Study in Tertiary Care Centre in India.

INTRODUCTION

Preterm infants are at great risk of neurological impairments. This study aimed to evaluate what is the difference in short- and long-term neonatal outcome comparing magnesium sulphate in small dose (4 g) versus controls.

METHODS

Prospective cohort study was conducted in the Department of Obstetrics and Gynaecology over a period of 4 years. Group A comprised of the study group (intravenous 4 g magnesium sulphate was given over 20 min). Group B consisted of control group who did not receive magnesium sulphate.

RESULTS

The study population comprised of 116 pregnant women who received intravenous bolus of 4 grams MgSO4 while the control group comprised of 95 pregnant women who did not receive MgSO4. Fewer neonates in the MgSO4 group required intubation at birth (32% vs. 52%) or chest compression (4% vs. 6%); however, the difference was not statistically significantly ( = 0.175 and  = 0.329). Neonatal brain ultrasound done in first month showed a significant reduction intraventricular haemorrhage of severe grade 3-4 IVH in the MgSO4 group ( = 0.016). MgSO4 administration was associated with a decrease in neonatal mortality before discharge ( = 0.039). Follow-up at 3 years showed a significant reduction in delayed milestones, visual impairment, Bayley score < 85 ( = 0.015). MgSO4 treatment antenatally was associated with lower risk of Cerebral Palsy (2.6% vs. 23.2%,  < 0.001).

CONCLUSION

The benefits from single smaller dose magnesium sulphate 4 gram prove its potential to be used for foetal neuroprotection in any healthcare setting without any maternal concerns.